|Day Low/High||5.29 / 5.33|
|52 Wk Low/High||3.60 / 5.74|
Jim Cramer says next week's earnings calendar is littered with brick-and-mortar roadkill.
Growth is obvious everywhere; yes, even in Italy or Latin America.
Bank stocks led the charge across Europe after hawkish Janet Yellen comments.
Bank increases its business hours by 13%, including additional hours on Saturdays, and redesigns its branches to improve the customer experience
Rating agency S&P upgraded the ratings and outlooks of a bunch of Spanish banks.
Jim Cramer likes European banks, plus Banco Santander, and New York Community Bancorp, too.
Jim Cramer takes a closer look at the risks: Don't measure 'Trump per share,' measure actual earnings per share.
Stocks in Frankfurt and London rose on Tuesday, while other major benchmarks closed in the red.
Spain's three largest lenders are facing regulatory changes and exposure to Mexico that are partly overshadowing an otherwise solid quarterly performance from one of Europe's largest banking sectors.
Germany's DAX led the pack on Wednesday, with the CAC 40 and FTSE 100 in tow.
News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.
Spain's biggest lender will be a hard act to follow as it kicked off Europe's bank reporting season by beating consensus profit forecasts by 9%.
See why Jim Cramer calls American Tower worth owning, even if the chart looks terrible.
Amazon.com has all the qualities we really want from our stocks - now, says Jim Cramer.
Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) and Boehringer Ingelheim's consumer...
New Grants Bring Santander's Total Community-Based Donations in 2016 to Nearly $10 Million
The key trends for 2016 were falling insulin prices, falling returns on R&D and lower approval rates, according to analysts at the French bank.
Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal antibody being studied for the...
Royal Bank of Scotland's stress-test failure marks another twist in a long and winding road to recovery for the beleaguered lender.
RBS misses both key targets in Bank of England tests, says it must "do more" to restore resilience.
A less stringent ECB capital target has investors betting on a bigger payout for shareholders.